Search form

Latest News

Quidel Receives FDA Clearance for Its Solana® RSV + hMPV Assay

SAN DIEGO--(BUSINESS WIRE)--Oct. 17, 2017--
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced today that it has received
clearance from the United States Food and Drug Administration (FDA) to
market its Solana® respiratory syncytial virus (“RSV”) +
human metapneumovirus (“hMPV”) Assay for the detection of nucleic acids
isolated from nasal and nasopharyngeal swabs from patients with signs
and symptoms of respiratory infection to aid in the diagnosis of RSV
and/or hMPV infections. The Solana® RSV + hMPV Assay is
intended for use only with the Solana® instrument.

Read More »


Are you a determined, optimistic, team player? Quidel is looking for talented innovators who want to be part of revolutionizing medical diagnostics.

View Current Job Openings


To place orders, get assistance with shipments, pricing or contract administration view our Customer Support page.

Visit our Technical Support page to get help with product specifications, supporting docs or general support issues.

NEW: Register at to download and install the latest Software Updates, Assay and testing capabilities for your Quidel Instruments.